keyword
MENU ▼
Read by QxMD icon Read
search

Cidp

keyword
https://www.readbyqxmd.com/read/29764262/igpro20-the-polyneuropathy-and-treatment-with-hizentra-%C3%A2-study-path-and-the-treatment-of-chronic-inflammatory-demyelinating-polyradiculoneuropathy-with-subcutaneous-igg
#1
Melvin Berger, Thomas Harbo, David R Cornblath, Orell Mielke
Subcutaneous IgG (SCIG) administration may be preferred over the intravenous route (IVIG) in chronic inflammatory demyelinating polyneuropathy (CIDP) because it minimizes 'end of cycle' treatment-related fluctuations, reduces systemic adverse effects, improves convenience/quality of life and potentially lowers overall costs. Early reports of the use of highly concentrated SCIG preparations suggested they were effective and well-tolerated in chronic inflammatory demyelinating polyneuropathy. This was confirmed in the Polyneuropathy and Treatment with Hizentra® study of 172 subjects randomized to receive maintenance therapy with placebo or one of two doses of IgPro20 (20% IgG stabilized with L-Proline) for 6 months...
May 16, 2018: Immunotherapy
https://www.readbyqxmd.com/read/29761119/antibodies-against-cell-adhesion-molecules-and-neural-structures-in-paraneoplastic-neuropathies
#2
Ana M Siles, Eugenia Martínez-Hernández, Josefa Araque, Jordi Diaz-Manera, Ricard Rojas-Garcia, Eduard Gallardo, Isabel Illa, Francesc Graus, Luis Querol
Objective: Paraneoplastic neurological syndromes (PNS) are rare neurological disorders in which ectopic expression of neural antigens by a tumor results in an autoimmune attack against the nervous system. Onconeural antibodies not only guide PNS diagnosis but may also help detecting underlying malignancies. Our project aims to uncover new potential antibodies in paraneoplastic neuropathies (PN). Methods: Thirty-four patients fulfilling diagnostic criteria of possible ( n = 9; 26...
May 2018: Annals of Clinical and Translational Neurology
https://www.readbyqxmd.com/read/29742800/reductions-in-muscle-quality-and-quantity-in-cidp-patients-assessed-by-magnetic-resonance-imaging
#3
Kevin J Gilmore, Timothy J Doherty, Kurt Kimpinski, Charles L Rice
INTRODUCTION: Weakness in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) may be caused by decreases in muscle quantity and quality, but these have not been explored. METHODS: Twelve patients with CIDP (mean 61 years) and ten age- matched (mean 59 years) control subjects were assessed for ankle dorsiflexion strength, and two different MRI scans (T1 and T2) of leg musculature. RESULTS: Isometric strength was lower in CIDP patients by 36% compared with controls...
May 9, 2018: Muscle & Nerve
https://www.readbyqxmd.com/read/29700616/chronic-inflammatory-demyelinating-polyneuropathy-evaluation-of-the-vestibular-system-with-cervical-and-ocular-vestibular-evoked-myogenic-potentials
#4
Giuseppe Magliulo, Giannicola Iannella, Alessandra Manno, Laura Libonati, Emanuela Onesti, Annarita Vestri, Danilo Alunni Fegatelli, Diletta Angeletti, Annalisa Pace, Giampiero Gulotta, Silvia Gagliardi, Maurizio Inghilleri
PURPOSE: To investigate the possibility of vestibular damage in a group of patients suffering from chronic inflammatory demyelinating polyneuropathy (CIDP) using a diagnostic protocol including the caloric test, C-VEMPs and O-VEMPs. METHODS: Twenty patients suffering from CIDP (mean age 58.5 years, range 33-80 years; 4 women and 16 men) were investigated. To assess any eventual audio-vestibular involvement, all patients of the study underwent pure tone audiometry, Fitzgerald-Hallpike caloric vestibular test, C-VEMPs and O-VEMPs...
April 27, 2018: European Archives of Oto-rhino-laryngology
https://www.readbyqxmd.com/read/29687027/head-and-voice-tremor-improving-with-immunotherapy-in-an-anti-nf155-positive-cidp-patient
#5
Cèlia Painous, Mª Ángeles López-Pérez, Isabel Illa, Luis Querol
Chronic inflammatory demyelinating polyradiculoneuropathy with NF155 antibodies (anti-NF155+) constitutes a specific chronic inflammatory demyelinating polyradiculoneuropathy subset with a high incidence of limb's tremor and poor response to conventional therapies. We report a patient with chronic inflammatory demyelinating polyradiculoneuropathy anti-NF155+ with a severe tremor involving limbs, head and voice that responded very well to rituximab. This response correlated with a sharp decrease in the anti-NF155 titers...
April 2018: Annals of Clinical and Translational Neurology
https://www.readbyqxmd.com/read/29670818/fingolimod-promotes-blood-nerve-barrier-properties-in-vitro
#6
Hideaki Nishihara, Toshihiko Maeda, Yasuteru Sano, Maho Ueno, Nana Okamoto, Yukio Takeshita, Fumitaka Shimizu, Michiaki Koga, Takashi Kanda
Objective: The main effect of fingolimod is thought to be functional antagonism of lymphocytic S1P1 receptors and the prevention of lymphocyte egress from lymphoid tissues, thereby reducing lymphocyte infiltration into the nervous system. However, a growing number of reports suggest that fingolimod also has a direct effect on several cell types in the nervous system. Although we previously reported that fingolimod enhances blood-brain barrier (BBB) functions, there have been no investigations regarding the blood-nerve barrier (BNB)...
April 2018: Brain and Behavior
https://www.readbyqxmd.com/read/29627036/nocebo-in-chronic-inflammatory-demyelinating-polyneuropathy-a-systematic-review-and-meta-analysis-of-placebo-controlled-clinical-trials
#7
Panagiotis Zis, Marios Hadjivassiliou, Ptolemaios G Sarrigiannis, Thomas M Jenkins, Dimos-Dimitrios Mitsikostas
INTRODUCTION: Nocebo is very prevalent among neurological disorders, resulting in low adherence and treatment outcome. We sought to examine the adverse events (AE) following placebo administration in placebo-controlled randomized clinical trials (RCTs) for chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: After a systematic literature search for RCTs for CIDP pharmacotherapy treatments, we assessed the number of AE in the placebo groups and the number discontinuations because of placebo intolerance...
May 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29618748/fingolimod-therapy-is-not-effective-in-a-mouse-model-of-spontaneous-autoimmune-peripheral-polyneuropathy
#8
Petra Huehnchen, Wolfgang Boehmerle, Matthias Endres
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disorder, which causes progressive sensory and motor deficits and often results in severe disability. Knockout of the co-stimulatory protein CD86 in mice of the non-obese diabetic background (NoD.129S4-Cd86tm1Shr /JbsJ) results in the development of a spontaneous autoimmune peripheral polyneuropathy (SAPP). We used this previously described transgenic model to study the effects of the sphingosine-1-phosphate receptor agonist fingolimod on SAPP symptoms, functional and electrophysiological characteristics...
April 4, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29615965/neurofascin-and-compact-myelin-antigen-specific-t-cell-response-pattern-in-chronic-inflammatory-demyelinating-polyneuropathy-subtypes
#9
Jan-Markus Diederich, Maximilian Staudt, Christian Meisel, Katrin Hahn, Edgar Meinl, Andreas Meisel, Juliane Klehmet
Objective: The objective of this study is to investigate whether chronic inflammatory demyelinating polyneuropathy (CIDP) and its subtypes differ in their type 1 T-helper (TH1) cell response against nodal/paranodal neurofascin (NF186, NF155) as well as myelin protein zero (P0 180-199) and myelin basic protein (MBP 82-100). Methods: Interferon-gamma (IFN-γ) enzyme-linked immunospot assay was used to detect antigen-specific T cell responses in 48 patients suffering typical CIDP ( n  = 18), distal acquired demyelinating polyneuropathy ( n  = 8), multifocal acquired demyelinating sensory and motor polyneuropathy (MADSAM; n  = 9), and sensory CIDP ( n  = 13) compared to other non-immune polyneuropathy (ON; n  = 19) and healthy controls ( n  = 9)...
2018: Frontiers in Neurology
https://www.readbyqxmd.com/read/29615658/systemic-igf-1-gene-delivery-by-raav9-improves-spontaneous-autoimmune-peripheral-polyneuropathy-sapp
#10
Tong Gao, Nataliia Bogdanova, Sameera Ghauri, Gang Zhang, Jianxin Lin, Kazim Sheikh
Spontaneous autoimmune peripheral polyneuropathy (SAPP) is a mouse model of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in non-obese diabetic (NOD) mice null for costimulatory molecule, B7-2 gene (B7-2-/- ). SAPP is a chronic progressive and multifocal inflammatory and demyelinating polyneuropathy of spontaneous onset with secondary axonal degeneration. Insulin-like growth factor 1(IGF-1) is a pleiotropic factor with neuroprotective, regenerative, and anti-inflammatory effects with extensive experience in its preclinical and clinical use...
April 3, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29603842/a-randomized-multicentre-phase-iii-study-of-three-different-doses-of-intravenous-immunoglobulin-10-in-patients-with-chronic-inflammatory-demyelinating-polyradiculoneuropathy-procid-trial-study-design-and-protocol
#11
David R Cornblath, Hans-Peter Hartung, Hans D Katzberg, Ingemar S J Merkies, Pieter A van Doorn
Patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) show varying degrees of response to intravenous immunoglobulin (IVIg) therapy. This randomised phase III study in patients with CIDP (ProCID trial) will compare the efficacy and safety of three different doses (0.5, 1.0 and 2.0 g/kg) of IVIg 10% (panzyga®) administered every 3 weeks for 24 weeks. The primary efficacy endpoint is the rate of treatment response, defined as a decrease in adjusted Inflammatory Neuropathy Cause and Treatment disability score of ≥1 point, in the IVIg 1...
March 30, 2018: Journal of the Peripheral Nervous System: JPNS
https://www.readbyqxmd.com/read/29603827/differences-between-acute-onset-chronic-inflammatory-demyelinating-polyneuropathy-a-cidp-and-acute-inflammatory-demyelinating-polyneuropathy-aidp-in-adult-patients
#12
Lucas Alessandro, José M Pastor Rueda, Miguel Wilken, Luis A Querol Gutiérrez, Mariano Marrodán, Julián N Acosta, Alberto Rivero, Fabio Barroso, Mauricio F Farez
Acute Inflammatory Demyelinating Polyneuropathy (AIDP) and Acute-onset Chronic Inflammatory Demyelinating Polyneuropathy (A-CIDP) are conditions presenting overlapping clinical features during early stages (first 4 weeks), although the latter may progress after 8 weeks. The aim of this study was to identify predictive factors contributing to their differential diagnosis. Clinical records of adult patients with AIDP or A-CIDP diagnosed at our institution between January-2006 and July-2017 were retrospectively reviewed...
March 30, 2018: Journal of the Peripheral Nervous System: JPNS
https://www.readbyqxmd.com/read/29603302/does-grip-strength-reflect-isokinetic-muscle-strength-in-lower-limbs-in-patients-with-chronic-inflammatory-demyelinating-polyneuropathy
#13
Kirsten L Knak, Linda K Andersen, Ingelise Christiansen, Lars K Markvardsen
INTRODUCTION: Grip strength (GS) is a common measure of general muscle strength in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). However, it is important to investigate the correlation and responsiveness of GS compared with isokinetic muscle strength (IKS) and function of the lower limbs. METHODS: Seventy patients with CIDP were evaluated with GS, IKS, and functional measures of the lower limbs. Reevaluation was performed after 2 and 10/12 weeks...
March 30, 2018: Muscle & Nerve
https://www.readbyqxmd.com/read/29573033/individualized-immunoglobulin-therapy-in-chronic-immune-mediated-peripheral-neuropathies
#14
REVIEW
Jeffrey A Allen, Melvin Berger, Luis Querol, Krista Kuitwaard, Robert D Hadden
Despite the well-recognized importance of immunoglobulin therapy individualization during the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), the pathway to best achieve optimization is unknown. There are many pharmacokinetic and immunobiologic variables that can potentially influence the appropriateness of any individual therapy. Although identification of specific autoantibodies and their targets has only been accomplished in a minority of patients with CIDP, already the diagnostic and treatment implications of specific autoantibody detection are being realized...
March 23, 2018: Journal of the Peripheral Nervous System: JPNS
https://www.readbyqxmd.com/read/29568686/transthyretin-familial-amyloid-polyneuropathy-ttr-fap-parameters-for-early-diagnosis
#15
Fabiola Escolano-Lozano, Ana Paula Barreiros, Frank Birklein, Christian Geber
Background: Familial transthyretin amyloidosis is a life-threatening disease presenting with sensorimotor and autonomic polyneuropathy. Delayed diagnosis has a detrimental effect on treatment and prognosis. To facilitate diagnosis, we analyzed data patterns of patients with transthyretin familial amyloid polyneuropathy (TTR-FAP) and compared them to polyneuropathies of different etiology for clinical and electrophysiological discriminators. Methods: Twenty-four patients with TTR-FAP and 48 patients with diabetic polyneuropathy (dPNP) were investigated (neurological impairment score NIS; neurological disability score NDS) in a cross-sectional design...
January 2018: Brain and Behavior
https://www.readbyqxmd.com/read/29554579/long-term-neurophysiological-and-clinical-response-in-patients-with-chronic-inflammatory-demyelinating-polyradiculoneuropathy-treated-with-subcutaneous-immunoglobulin
#16
Giovanni Cirillo, Vincenzo Todisco, Gioacchino Tedeschi
OBJECTIVE: To assess the long-term effects of subcutaneous immunoglobulin (SCIg) on neurophysiological and clinical parameters in patients affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). METHODS: 16 drug-naïve CIDP patients, fulfilling the clinical and neurophysiological criteria for typical CIDP, were treated with one cycle of intravenous immunoglobulin (IVIg) (0.4 g/kg/day for 5 consecutive days) and then shifted to the subcutaneous treatment (SCIg) (0...
February 19, 2018: Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology
https://www.readbyqxmd.com/read/29552093/high-resolution-nerve-ultrasound-and-magnetic-resonance-neurography-as-complementary-neuroimaging-tools-for-chronic-inflammatory-demyelinating-polyneuropathy
#17
Kalliopi Pitarokoili, Moritz Kronlage, Philip Bäumer, Daniel Schwarz, Ralf Gold, Martin Bendszus, Min-Suk Yoon
Background: We present a clinical, electrophysiological, sonographical and magnetic resonance neurography (MRN) study examining the complementary role of two neuroimaging methods of the peripheral nervous system for patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Furthermore, we explore the significance of cross-sectional area (CSA) increase through correlations with MRN markers of nerve integrity. Methods: A total of 108 nerve segments on the median, ulnar, radial, tibial and fibular nerve, as well as the lumbar and cervical plexus of 18 CIDP patients were examined with high-resonance nerve ultrasound (HRUS) and MRN additionally to the nerve conduction studies...
2018: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/29541543/challenges-in-the-diagnosis-of-chronic-inflammatory-demyelinating-polyneuropathy
#18
Jeffrey A Allen, Kenneth C Gorson, Deborah Gelinas
Introduction: We explored adherence to the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) by reviewing data from a specialty pharmacy database. Materials and Methods: Clinical and electrophysiologic data were reviewed for 65 consecutive patients treated with intravenous immunoglobulin (IVIG) for CIDP. Three neuromuscular neurologists independently classified cases according to EFNS/PNS criteria as (1) fulfilling CIDP criteria; (2) non-CIDP (neither clinical nor electrophysiologic criteria met); or (3) unknown (insufficient information)...
March 2018: Brain and Behavior
https://www.readbyqxmd.com/read/29517417/octagam-%C3%A2-for-chronic-inflammatory-demyelinating-polyneuropathy-results-from-three-observational-studies
#19
Stefan Wietek
AIM: To present data from three studies of a Post-Authorization Safety Surveillance (PASS) program for the subset of patients receiving octagam® 5% or 10% for chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: Data on patients with CIDP treated with octagam were analyzed to assess its safety and tolerability. RESULTS: Of 2314 patients included in the studies, 58 patients (mean age: 64.6 years) received octagam for CIDP, mean dose of which was 0...
March 8, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29501083/the-clinical-features-of-combined-central-and-peripheral-demyelination-in-chinese-patients
#20
Yan-Qin Wang, Han Chen, Wu-Ping Zhuang, Hong-Lei Li
BACKGROUND: Combined central and peripheral demyelination (CCPD) is rare and has never been reported as a spectrum disease in Han Chinese population. OBJECTIVES: To study the clinical features of CCPD in Han Chinese patients. METHODS: Twenty-two CCPD patients were selected from 788 demyelination cases. We reviewed and compared the clinical manifestation, laboratory data, electrophysiological examination, MRI and the prognosis. RESULTS: CCPD patients presented with sensory disturbance (86...
April 15, 2018: Journal of Neuroimmunology
keyword
keyword
8992
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"